Sunesis Pharmaceuticals to Present Data on Clinical-Stage Product Candidates at the Annual Meeting of the American Association
March 29 2006 - 8:30AM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., March 29 /PRNewswire-FirstCall/ --
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that
the company will present five posters during the upcoming Annual
Meeting of the American Association for Cancer Research (AACR)
being held in Washington D.C. April 1-5, 2006. Four of the posters
being presented focus on preclinical and clinical data from
Sunesis' study of SNS-595, a first-in-class therapeutic that acts
selectively through DNA-PK signaling in the S phase of the cell
cycle to kill proliferating cancer cells by inducing apoptosis, or
programmed cell death. Data from the company's studies of SNS-032,
a novel targeted inhibitor of certain cyclin-dependent kinases that
are critical in the promotion of cellular growth and function, will
also be presented. Monday, April 3, 2006 -- SNS-595 has synergistic
activity in vitro with DNA-damaging agents and antimetabolites
Abstract Number: 2132 -- SNS-595 causes selective double-strand
breaks during S phase which are solely repaired through
non-homologous end joining Abstract Number: 2074 -- SNS-032 is a
potent and selective inhibitor of CDK 2, 7 and 9 and induces cell
death by inhibiting cell cycle progression and the expression of
antiapoptotic proteins Abstract Number: 2079 -- A phase 1 trial of
weekly SNS-595 in patients (pts) with refractory cancer Abstract
Number: 2913 Tuesday, April 4, 2006 -- SNS-595, a novel S-phase
active cytotoxic, exhibits potent in vitro and in vivo activities,
and has the potential for treating advanced hematologic
malignancies Abstract Number: 4726 About Sunesis' Oncology Programs
Sunesis has built a portfolio of preclinical- and development-stage
product candidates in oncology focused on novel pathways and
targets, including inhibition of the cell cycle and survival
signaling. Sunesis is currently conducting Phase II and Phase I
clinical trials in lung cancer and acute leukemia for its lead
compound, SNS-595. SNS-595 is a novel napthyridine analog, a class
of compounds not previously used for cancer treatment. SNS-595 acts
selectively through DNA-PK signaling in the S-phase of the cell
cycle to kill proliferating cancer cells by inducing apoptosis, or
programmed cell death. SNS-032 is in a Phase I/II clinical studies
to examine the safety and preliminary anti-tumor activity among
patients with lung cancer, breast cancer or melanoma. SNS-032 is a
potent and selective inhibitor of cyclin-dependent kinases 2, 7 and
9. Sunesis is currently conducting preclinical studies of its
Aurora kinase inhibitor drug candidate, SNS-314. In addition, in
cooperation with Biogen Idec, Sunesis is developing novel small
molecule inhibitors of Raf kinase and other oncology kinases. About
Sunesis Pharmaceuticals Sunesis is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel small molecule therapeutics for oncology
and other serious diseases. Sunesis has built a broad product
candidate portfolio through internal discovery and in-licensing of
novel cancer therapeutics. Sunesis is advancing its product
candidates through in-house research and development efforts and
strategic collaborations with leading pharmaceutical and
biopharmaceutical companies. Forward-Looking Statements This press
release may contain forward-looking statements that involve
substantial risks and uncertainties. Sunesis may not actually
achieve the plans, intentions or expectations contained in such
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations contained in
such forward-looking statements. Sunesis does not assume any
obligation to update any such forward-looking statements. For
further information on Sunesis Pharmaceuticals, please visit
http://www.sunesis.com/ . DATASOURCE: Sunesis Pharmaceuticals, Inc.
CONTACT: investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals,
Inc., +1-650-266-3717; or media, Karen L. Bergman, +1-650-575-1509,
or Michelle Corral, +1-415-794-8662, both of BCC Partners for
Sunesis Pharmaceuticals, Inc. Web site: http://www.sunesis.com/
Copyright
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Sunesis Pharmaceuticals (MM) News Articles